Education
About Us
Working with TipRanks
Follow Us
Laboratorios Farmaceuticos Rovi, SA (GB:0ILL)
LSE:0ILL
Earnings Data
Report Date
Nov 06, 2025TBA (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
―Last Year’s EPS
0.86Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call reflected both positive and negative trends. The Specialty Pharma business showed strong growth, particularly in products like Okedi and heparin, and the company is expanding its technological capabilities. However, overall revenue decreased due to significant declines in the CDMO segment, and profitability metrics like EBITDA and net profit also fell. The company's strategic focus on long-term growth and innovation is evident, but immediate financial challenges persist.Company Guidance
Specialty Pharma Business Growth
Sales of the Specialty Pharma business increased by 13% to EUR 237.4 million in the first half of 2025, driven by products like Okedi, Neparvis, and heparin divisions.
Okedi Sales Surge
Okedi sales increased by 115% to EUR 26.9 million in the first half of 2025 compared to the same period in 2024, showing a robust growth trajectory.
Heparin Division Performance
The heparin division saw a 12% sales increase to EUR 135.2 million, with enoxaparin sales rising 14% due to stronger international sales.
Gross Margin Improvement
Gross margin increased by 3 percentage points to 62.4% in the first half of 2025, driven by product mix and reduced raw material costs.
Technological Development and Innovation Center Aid
Award of aid of EUR 36.3 million for ROVI's LAISOLID project, covering development costs from January 2023 to August 2026.
Expansion in AI and Pathological Anatomy
Acquired a majority position in Cells IA Technologies, enhancing ROVI's capabilities in AI-assisted diagnosis for pathological anatomy.
Laboratorios Farmaceuticos Rovi (GB:0ILL) Earnings, Revenues Date & History
GB:0ILL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:0ILL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jul 24, 2025 | €54.39 | €56.54 | +3.95% |
May 08, 2025 | €50.50 | €53.02 | +4.99% |
Feb 25, 2025 | €54.50 | €54.26 | -0.44% |
Nov 07, 2024 | €74.28 | €65.45 | -11.89% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Laboratorios Farmaceuticos Rovi, SA (GB:0ILL) report earnings?
Laboratorios Farmaceuticos Rovi, SA (GB:0ILL) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).
What is Laboratorios Farmaceuticos Rovi, SA (GB:0ILL) earnings time?
Laboratorios Farmaceuticos Rovi, SA (GB:0ILL) earnings time is at Nov 06, 2025, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Laboratorios Farmaceuticos Rovi, SA stock?
The P/E ratio of Laboratorios Farmaceuticos Rovi is N/A.
What is GB:0ILL EPS forecast?
Currently, no data Available